newsfilter
← Latest News
GlobeNewswire·

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today,